$INSP News

Inspire Medical Systems, Inc. 2026 Q2 - Results - Earnings Call Presentation

Oppenheimer Upgrades Inspire Medical Systems (INSP)

JP Morgan Maintains Neutral on Inspire Medical Systems, Raises Price Target to $60

Mizuho Maintains Outperform on Inspire Medical Systems, Raises Price Target to $65

Oppenheimer Upgrades Inspire Medical Systems to Outperform, Announces $85 Price Target

Truist Securities Reiterates Hold on Inspire Medical Systems, Raises Price Target to $62

Inspire Medical Systems (INSP) Price Target Decreased by 10.76% to 62.63

Evercore ISI Group Maintains In-Line on Inspire Medical Systems, Raises Price Target to $54

Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results

Piper Sandler Maintains Neutral on Inspire Medical Systems, Raises Price Target to $60

Baird Maintains Neutral on Inspire Medical Systems, Raises Price Target to $59

Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems Lowers FY2026 GAAP EPS Guidance from $0.07-$0.62 to $(0.42)-$0.17 vs $0.90 Est

Inspire Medical Systems Raises FY2026 Adj EPS Guidance from $0.75-$1.25 to $1.05-$1.45 vs $0.38 Est; Raises FY2026 Sales Guidance from $825.000M-$875.000M to $835.000M-$875.000M vs $843.387M Est

Inspire Medical Systems Q2 Adj. EPS $0.14 Beats $(0.27) Estimate, Sales $200.581M Beat $194.671M Estimate

UBS Assumes Inspire Medical Systems at Sell, Lowers Price Target of $39

Truist Securities Maintains Hold on Inspire Medical Systems, Raises Price Target to $54

Freedom Capital Markets Initiates Coverage of Inspire Medical Systems (INSP) with Buy Recommendation

Freedom Capital Markets Initiates Coverage On Inspire Medical Systems with Buy Rating, Announces Price Target of $62

Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript